AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales ... coupled with a long history of innovation, is a big part of what makes AbbVie a blue chip stock and compelling ...

Investors in AbbVie Inc. ABBV need to pay close attention ... It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is ...

Pharmaceutical giant AbbVie has inked another collaboration deal ... has also signed similar agreements with other Big Pharma companies, such as Novo Nordisk and Biogen. The company focuses ...

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies ...

Global healthcare giant AbbVie stands out with its robust drug ... Despite these clear risks, I own this high-yielding big pharma stock because I believe its global reach and vast product ...